Since the primary goal of neoantigen identification (in the context of cancer vaccines development) is to select those that would trigger or boost T-cell-mediated immune response (preferably CD8+ T cell response), it is essential to know which of the peptides with a high MHC binding affinity will be recognized by T-cells. Here, HLA-C is linked to cancer.